Translational Neurodegeneration

Translational Neurodegeneration: 10th Anniversary

2022 marks the 10th anniversary of Translational Neurodegeneration.

To celebrate, we have put together a page to review the achievements and highlights of the journal.

Featured articles

Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy

Advances in the development of new biomarkers for Alzheimer’s disease

A review of brain imaging biomarker genomics in Alzheimer’s disease: implementation and perspectives

Authors: Lanlan Li, Xianfeng Yu, Can Sheng, Xueyan Jiang, Qi Zhang, Ying Han and Jiehui Jiang

Content type: Review 15 September 2022
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease

Authors: Hanseul Park, Jaein Shin, Yunkyung Kim, Takashi Saito, Takaomi C. Saido and Jongpil Kim

Content type: Research 15 September 2022
The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms

Authors: Feng Chen, Yanting Chen, Yongxiang Wang, Qiongwei Ke and Lili Cui

Content type: Review 11 September 2022
The emerging role of furin in neurodegenerative and neuropsychiatric diseases

Authors: Yi Zhang, Xiaoqin Gao, Xue Bai, Shanshan Yao, Yan-Zhong Chang and Guofen Gao

Content type: Review 23 August 2022
Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease

Authors: Matilde Bongianni, Mauro Catalan, Daniela Perra, Elena Fontana, Francesco Janes, Claudio Bertolotti, Luca Sacchetto, Stefano Capaldi, Matteo Tagliapietra, Paola Polverino, Valentina Tommasini, Giulia Bellavita, Elham Ataie Kachoie, Roberto Baruca, Andrea Bernardini, Mariarosaria Valente…

Content type: Research 28 July 2022

The Correction to this article has been published in Translational Neurodegeneration 2022 11:38

Most recent articles RSS

View all articles

2022

Thematic series
Recent progresses on early diagnosis of Parkinson’s disease and related disorders
Edited by Anthony E. Lang

Thematic series
Clearance of neurotoxic proteins in proteinopathies: from clearance pathways to therapeutic targets
Edited by Shengdi Chen

Thematic series
PD progresses in recent 10 years: from hypothesis to therapeutic targets
Edited by Shengdi Chen

Thematic series
AD progresses in recent 10 years: from hypothesis to therapeutic targets
Edited by Weihong Song

2021

Thematic series
MicroRNAs and neurodegenerative diseases
Edited by Zixu Mao

Thematic series
Mitochondria dysfunctions and neurodegenerative diseases
Edited by Xiongwei Zhu

2015

Thematic series
Update on Amyotrophic lateral sclerosis: from genetic and mitochondria perspective
Edited by Shengdi Chen and Jialin Zheng

Thematic series
Stem cell-based therapy for Alzheimer’s disease: the current situation and future prospects

Thematic series
Pharmacological treatment for early and advanced stages of Parkinson’s disease: current and future strategies
Edited by Shengdi Chen and Jialin Zheng

2014

Cross journal collection
Reviewer acknowledgements 2013

Editor-in-Chief

Shengdi Chen, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China

Aims and Scope

Translational Neurodegeneration is an open access, peer-reviewed journal that covers research, therapeutics and education for all aspects of neurodegenerative diseases. By offering a high-visibility forum for new insights and discussions, Translational Neurodegeneration creates a novel interface between the fields of basic, translational, and clinical research. It includes Parkinson's disease and movement disorders, Alzheimer's disease and other dementias, motor neuron disease and other neurodegenerative diseases.

Announcing the launch of In Review

Translational Neurodegeneration, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:

Share their work with fellow researchers to read, comment on, and cite even before publication
Showcase their work to funders and others with a citable DOI while it is still under review
Track their manuscript - including seeing when reviewers are invited, and when reports are received

See the full range of benefits of In Review and how to opt-in

See what the In Review platform looks like

Translational Neurodegeneration